Home > Riviste > Minerva Cardiology and Angiology > Fascicoli precedenti > Articles online first > Minerva Cardiology and Angiology 2021 Apr 07



Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Cardiology and Angiology 2021 Apr 07

DOI: 10.23736/S2724-5683.21.05669-6


lingua: Inglese

Intracoronary bolus of glycoprotein IIb/IIIa inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of STEMI

Mattia GALLI 1, 2 , Stefano MIGLIARO 1, Daniele RODOLICO 1, Gaetano DI STEFANO 1, Carlo PICCINNI 1, Attilio RESTIVO 1, Felicita ANDREOTTI 1, 2, Rocco VERGALLO 1, Rocco A. MONTONE 1, 2, George BESIS 1, Antonio BUFFON 1, 2, Enrico ROMAGNOLI 1, Cristina AURIGEMMA 1, Antonio M. LEONE 1, 2, Francesco BURZOTTA 1, 2, Giampaolo NICCOLI 1, 2, Carlo TRANI 1, 2, Filippo CREA 1, 2, Domenico D'AMARIO 1

1 Dipartimento di Scienze Cardiovascolari e Toraciche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 2 Università Cattolica del Sacro Cuore, Rome, Italy


BACKGROUND: In the acute management of ST-elevation myocardial infarction (STEMI), glycoprotein IIb/IIIa inhibitors (GPIs) bolus not followed by intravenous infusion is potentially advantageous given their fast onset and offset of action, but clinical evidence in a contemporary setting is limited.
METHODS: We collected data from consecutive STEMI patients admitted to the cardiac catheterization laboratory of the Fondazione Policlinico Universitario A. Gemelli from October 2017 to September 2019.
RESULTS: Out of 423 consecutive STEMI patients, 297 met the inclusion and exclusion criteria and were included in the study. Of them, 107/297 (36%) received an intracoronary GPI bolus-only during primary percutaneous coronary intervention (PPCI) not followed by intravenous infusion and 190/297 (64%) received standard antithrombotic therapy. Of the 107 GPI-treated, 22/107 (21%) had P2Y12 inhibitor pre-treatment (adjunctive strategy) and 85/107 (79%) did not (bridging strategy). During hospital staying, there was no difference in the primary safety endpoint of TIMI major+minor bleeding (p=0.283), TIMI major (p=0.267) or TIMI minor (p=0.685) bleeding between groups. No stroke event occurred in the GPI group. Despite patients receiving GPI having a significantly higher intraprocedural ischemic burden, no significant differences were found in the efficacy outcomes between groups. Consistent findings were observed for patients receiving GPIs bolus before (bridging strategy) or after (adjunctive strategy) P2Y12 inhibitors, compared to those receiving standard therapy. Multivariate logistic regression analyses did not find any independent predictors significantly associated to the primary and secondary composite endpoints.
CONCLUSIONS: In a contemporary real-world population of STEMI patients undergoing PPCI, the use of intracoronary GPIs bolus-only in selected patients at high ischemic risk is safe and could represent a useful antithrombotic strategy both in those pre-treated and in those naïve to P2Y12 inhibitors.

KEY WORDS: STEMI; antiplatelet; Glycoprotein IIb/IIIa inhibitor; P2Y12 inhibitor; Bridging

inizio pagina